A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
More than 70 FDA-approved cancer drugs are kinase inhibitors, which work by blocking kinases-;enzymes that add phosphate groups to molecules in the cell-;and preventing the chemical activity necessary for signaling and growth in cancer cells.
The most frequent type of malignancy in kids is acute lymphoblastic leukemia (ALL).
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukemia cells.
While cancer therapies that target specific genes or disease pathways might prolong life span, they can also result in highly resistant tumors when tiny reservoirs of cancer cells survive therapy, develop, and spread.
Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
Australian scientists have found what could prove to be a new and effective way to treat a particularly aggressive blood cancer in children.
The biological clock is present in almost all cells of an organism. As more and more evidence emerges that clocks in certain organs could be out of sync, there is a need to investigate and reset these clocks locally.
Personalized treatment options for patients with lung cancer have come a long way in the past two decades. For patients with non-small cell lung cancer, the most common subtype of lung cancer and the leading cause of cancer-related death worldwide, two major treatment strategies have emerged: tyrosine kinase inhibitors and immune checkpoint inhibitors.
Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.
An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients, according to first results of a phase 3 clinical trial. The pivotal study could lead to a new treatment option for patients with metastatic kidney cancer.
A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).